论文部分内容阅读
目的观察地塞米松联合氨溴索(沐舒坦)治疗新生儿重症吸入性肺炎的临床效果。方法选取2010年7月—2013年7月我院收治的新生儿重症吸入性肺炎患儿130例,按照随机数字表法将其分为观察组70例和对照组60例。对照组采取地塞米松治疗,观察组在此基础上联合沐舒坦治疗。比较两组患儿临床效果,并观察两组通气时间、住院时间以及氧疗时间。结果对照组总有效率为71.7%(43/60),低于观察组的94.3%(66/70)(P<0.05)。观察组通气时间、住院时间以及氧疗时间均短于对照组(P<0.05)。结论地塞米松联合沐舒坦治疗新生儿重症吸入性肺炎疗效显著,临床价值较高。
Objective To observe the clinical effect of dexamethasone combined with ambroxol in the treatment of neonatal severe aspiration pneumonia. Methods From July 2010 to July 2013, 130 children with severe neonatal pneumonia admitted to our hospital were randomly divided into observation group (70 cases) and control group (60 cases) according to random number table method. Control group to take dexamethasone treatment, the observation group on this basis combined with mucosolvan treatment. The clinical effects of the two groups were compared, and the duration of ventilation, hospitalization and oxygen therapy were observed. Results The total effective rate was 71.7% (43/60) in the control group, which was lower than 94.3% (66/70) in the observation group (P <0.05). The observation group ventilation time, hospital stay and oxygen treatment time were shorter than the control group (P <0.05). Conclusion dexamethasone combined with ambroxol treatment of neonatal severe aspiration pneumonia has a significant effect, high clinical value.